EFX Stock Recent News

Equifax (EFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts expect Equifax Inc.'s Q1 '25 results to show minimal growth, with EPS estimates at $1.41 adjusted and $1.00 GAAP on $1.42B revenue. Key concerns include weak U.S. mortgage and hiring markets, with 16 downward EPS revisions adding uncertainty to the upcoming results. Focus areas include U.S. mortgage inquiry declines, Workforce Solutions headwinds, and international performance, particularly in Brazil and Europe.

Third Annual Report Provides Unique Equifax Cloud™-based Insights to Help Lenders Around the World Make More Informed Decisions and Innovate Faster ATLANTA , April 11, 2025 /PRNewswire/ --  Equifax ® (NYSE: EFX) has released its 2024 Global Consumer Credit Trends , a report that features global consumer credit data and trends information from 10 different countries including Australia, Brazil, Canada, India, Spain and the United States. The third annual report, made possible by the Equifax Cloud ™ and the company's custom data fabric, is designed to give lenders around the world a deeper view into overall consumer credit demand, debt, delinquencies, credit card utilization rates and inflation trends in their particular region to make more informed decisions and innovate faster – enabling more mainstream financial opportunities for consumers.

The EFX stock is gaining from its ability to sustain top-line growth momentum, fueled by synergies from buyouts and product innovation.

Investors with an interest in Consulting Services stocks have likely encountered both Information Services Group (III) and Equifax (EFX). But which of these two stocks presents investors with the better value opportunity right now?

Akero Therapeutics' EFX showed remarkable efficacy in reversing cirrhosis in the long-term SYMMETRY trial, a significant milestone in MASH treatment. EFX demonstrated consistent efficacy across different MASH stages, positioning it uniquely against competitors like Resmetirom, which only targets F2 and F3 MASH. Akero's financial health is strong, with a cash runway until 2028, bolstered by a recent $350 million upsized offering.

ATLANTA , April 3, 2025 /PRNewswire/ -- Equifax ® (NYSE: EFX) will announce its financial results for the first quarter ended March 31, 2025, in a release to be issued on Tuesday, April 22, at 6:30 a.m. Eastern Time (ET).

AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.

Fifth Annual Report Illustrates Continued Commitment to Cybersecurity Leadership and Innovation ATLANTA , March 27, 2025 /PRNewswire/ -- Equifax ® (NYSE: EFX) has released its 2024 Security Annual Report , highlighting its continued commitment to transparency, collaboration and innovation. For the fifth consecutive year, the report gives a look into how the organization has doubled down on security and the measures it has implemented to face today's cyber threats, including an industry-leading passwordless authentication transformation.

Despite beating the number in each of the last four quarters, estimates have fallen along with the Zacks Rank for this stock.